JP6774435B2 - 抗ウイルス活性を有する鼻づまり解除組成物 - Google Patents

抗ウイルス活性を有する鼻づまり解除組成物 Download PDF

Info

Publication number
JP6774435B2
JP6774435B2 JP2017565990A JP2017565990A JP6774435B2 JP 6774435 B2 JP6774435 B2 JP 6774435B2 JP 2017565990 A JP2017565990 A JP 2017565990A JP 2017565990 A JP2017565990 A JP 2017565990A JP 6774435 B2 JP6774435 B2 JP 6774435B2
Authority
JP
Japan
Prior art keywords
aqueous solution
carrageenan
solution according
nasal
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017565990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523635A5 (enExample
JP2018523635A (ja
Inventor
グラッサウアー，アンドレアス
プリィシゥル‐グラッサウアー，エバ
ボーデンタイヒ，アンジェリカ
コーラー，クリスチャーヌ
モロクッティ‐クルツ，マーティーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marinomed Biotech AG
Original Assignee
Marinomed Biotechnologie GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marinomed Biotechnologie GmbH filed Critical Marinomed Biotechnologie GmbH
Publication of JP2018523635A publication Critical patent/JP2018523635A/ja
Publication of JP2018523635A5 publication Critical patent/JP2018523635A5/ja
Application granted granted Critical
Publication of JP6774435B2 publication Critical patent/JP6774435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2017565990A 2015-07-14 2016-07-12 抗ウイルス活性を有する鼻づまり解除組成物 Active JP6774435B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15176670 2015-07-14
EP15176670.6 2015-07-14
PCT/EP2016/066565 WO2017009351A1 (en) 2015-07-14 2016-07-12 Stuffy nose deblocking composition having antiviral activity

Publications (3)

Publication Number Publication Date
JP2018523635A JP2018523635A (ja) 2018-08-23
JP2018523635A5 JP2018523635A5 (enExample) 2019-07-18
JP6774435B2 true JP6774435B2 (ja) 2020-10-21

Family

ID=53717900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017565990A Active JP6774435B2 (ja) 2015-07-14 2016-07-12 抗ウイルス活性を有する鼻づまり解除組成物

Country Status (26)

Country Link
US (1) US10660914B2 (enExample)
EP (1) EP3370692B1 (enExample)
JP (1) JP6774435B2 (enExample)
KR (1) KR102628781B1 (enExample)
CN (1) CN107847430B (enExample)
AU (1) AU2016293004B2 (enExample)
BR (1) BR112018000592B1 (enExample)
CA (1) CA2992352C (enExample)
CL (1) CL2018000033A1 (enExample)
DK (1) DK3370692T3 (enExample)
EA (1) EA037085B1 (enExample)
ES (1) ES2949139T3 (enExample)
FI (1) FI3370692T3 (enExample)
HU (1) HUE062108T2 (enExample)
IL (1) IL256883B (enExample)
LT (1) LT3370692T (enExample)
MA (1) MA43155A (enExample)
MX (1) MX372625B (enExample)
MY (1) MY194870A (enExample)
NZ (1) NZ738597A (enExample)
PH (1) PH12018500044B1 (enExample)
PL (1) PL3370692T3 (enExample)
PT (1) PT3370692T (enExample)
SA (1) SA518390689B1 (enExample)
WO (1) WO2017009351A1 (enExample)
ZA (1) ZA201708595B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11357791B2 (en) * 2016-02-17 2022-06-14 Ent Technologies Pty Ltd Compositions and methods for the treatment of sinus disease and disorders
GB2567285A (en) * 2017-08-07 2019-04-10 Suprapharm Cc Preparation for nasal-nasopharyngeal treatment
WO2021262141A1 (en) * 2020-06-22 2021-12-30 Mario Elmen Tremblay Personal lubricants comprising lambda-carrageenan
JP2023517239A (ja) 2020-03-12 2023-04-24 デイヴィッド カリス－ヒル、シドニー コロナウイルス感染症および関連するサイトカイン毒性の治療
CN111437270A (zh) * 2020-04-24 2020-07-24 瑞希(重庆)生物科技有限公司 一种卡拉胶鼻用即型凝胶喷雾剂及其制备方法
US11013687B1 (en) 2020-06-08 2021-05-25 Amcyte Pharma, Inc. Preventive and therapeutic treatment for COVID 19 and any other disease caused by SARS CoV 2
WO2021253643A1 (zh) * 2020-06-18 2021-12-23 大连工业大学 硫酸化多糖在抗新型冠状病毒中的应用
CN111686125A (zh) * 2020-06-18 2020-09-22 大连工业大学 卡拉胶在抗新型冠状病毒中的应用
EP3939597A1 (en) * 2020-07-16 2022-01-19 Marinomed Biotech AG Antiviral pharmaceutical composition comprising a carrageenan component
EP4192424A1 (fr) 2020-08-04 2023-06-14 Cosmosoft Hydrogel comprenant du glycerol et un carbomere pour le traitement par voie nasale des symptomes respiratoires de la maladie covid-19
FR3113237B1 (fr) 2020-08-04 2023-06-09 Biopass Produit pour le traitement de maladies virales par voie nasale
DE202020004186U1 (de) * 2020-10-05 2020-10-21 Christian Fleischhammel Antiinfektive Arzneiform zur Herstellung einer Nasenspülung gegen COVID-19
EP3991561A1 (en) * 2020-10-28 2022-05-04 Vepidan ApS Antimicrobial disinfectant gel
GB202109888D0 (en) 2021-07-08 2021-08-25 Pollinner Ltd Nasal spray
KR102720037B1 (ko) * 2021-12-21 2024-10-22 (주)메디코어 비강 세정제 조성물 및 그 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
US6080783A (en) * 1998-09-01 2000-06-27 Gum Tech International, Inc. Method and composition for delivering zinc to the nasal membrane
PL2486942T3 (pl) * 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US20080241271A1 (en) * 2006-11-08 2008-10-02 Roman Stephen B Foaming anti-adhesion composition
SI2101792T1 (sl) 2006-12-05 2010-08-31 Marinomed Biotechnologie Gmbh Uporaba karagenana za zdravljenje rinovirusnih infekcij
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
SI2178533T1 (sl) 2007-08-24 2013-07-31 Marinomed Biotechnologie Gmbh Antivirusni sestavek, ki obsega sulfatiran polisaharid: iota-karagenan
WO2009060915A1 (ja) * 2007-11-06 2009-05-14 San-Ei Gen F.F.I., Inc. 唾液分泌促進剤
FR2926218B1 (fr) * 2008-01-10 2010-08-13 Galderma Res & Dev Composition comprenant un retinoide et du peroxyde de benzoyle disperse.
WO2013049538A1 (en) * 2011-09-30 2013-04-04 Mcneil-Ppc, Inc. Allergen nasal compositions

Also Published As

Publication number Publication date
ES2949139T3 (es) 2023-09-25
KR102628781B1 (ko) 2024-01-24
EP3370692B1 (en) 2023-04-12
AU2016293004A1 (en) 2018-01-18
US20190060358A1 (en) 2019-02-28
IL256883A (en) 2018-03-29
MA43155A (fr) 2018-09-12
WO2017009351A1 (en) 2017-01-19
DK3370692T3 (da) 2023-06-26
CA2992352A1 (en) 2017-01-19
PT3370692T (pt) 2023-07-18
PH12018500044B1 (en) 2022-04-27
MY194870A (en) 2022-12-21
CN107847430A (zh) 2018-03-27
CA2992352C (en) 2023-06-27
EA201890196A1 (ru) 2018-06-29
HK1253038A1 (zh) 2019-06-06
AU2016293004B2 (en) 2021-05-06
SA518390689B1 (ar) 2021-07-17
CN107847430B (zh) 2021-02-02
PL3370692T3 (pl) 2023-08-14
HUE062108T2 (hu) 2023-09-28
PH12018500044A1 (en) 2018-07-23
KR20180054570A (ko) 2018-05-24
LT3370692T (lt) 2023-07-10
MX372625B (es) 2020-05-12
JP2018523635A (ja) 2018-08-23
MX2018000285A (es) 2018-02-19
CL2018000033A1 (es) 2018-08-10
IL256883B (en) 2021-07-29
FI3370692T3 (fi) 2023-06-16
US10660914B2 (en) 2020-05-26
ZA201708595B (en) 2021-06-30
EA037085B1 (ru) 2021-02-04
BR112018000592A2 (pt) 2018-09-11
BR112018000592B1 (pt) 2024-02-06
NZ738597A (en) 2021-12-24
EP3370692A1 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
KR102628781B1 (ko) 항바이러스 활성을 갖는 코막힘 차단해제 조성물
US20090191288A1 (en) Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
US20020165277A1 (en) Virucidal compositions
ES2834985T3 (es) Composición que contiene cineol para administración nasal
RS49721B (sr) Kompozicija koja sadrži biljku i površinski aktivno sredstvo korisna u proizvodnji proizvoda za tretiranje herpesa i drugih mikrobnih infekcija
BR122014006936B1 (pt) Composiçao farmaceutica compreendendo na forma de um anel intravaginal
US9662360B2 (en) Treatment of herpes, pseudomonas, staph, and hepatitis
US20230147530A1 (en) Antiviral Composition for Oral Care
EP1372389B1 (en) Virucidal compositions
CN116615180B (zh) 用于治疗和/或预防病毒感染的羟基磷灰石组合物
US20170274083A1 (en) Nasal composition having anti-viral properties
HK1253038B (en) Stuffy nose deblocking composition having antiviral activity
CN114288307A (zh) 一种含唾液酸盐的产品及其应用
EP2985027B1 (en) Nasal composition comprising mixture of hyaluronic acids and saline solution
SA90110074B1 (ar) تركيبات صيدلانية متضمنة على محلول مائي من مشتق بيرانوكوينولين pyranoquinoline
RU2780109C1 (ru) Противовоспалительные глазные капли для домашних и сельскохозяйственных животных
WO2022189630A1 (en) Composition for treatment and/or prevention of a corona virus infection
PL220390B1 (pl) Profilaktyczno higieniczny środek do płukania i nawilżania nosa

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201002

R150 Certificate of patent or registration of utility model

Ref document number: 6774435

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250